Compare IE & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IE | SUPN |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.9B |
| IPO Year | 2022 | 2012 |
| Metric | IE | SUPN |
|---|---|---|
| Price | $19.13 | $49.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $18.50 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 1.7M | 609.1K |
| Earning Date | 02-26-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,680,000.00 | ★ $681,539,000.00 |
| Revenue This Year | $26.75 | $8.32 |
| Revenue Next Year | $27.74 | $23.64 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.58 | 4.54 |
| 52 Week Low | $4.50 | $29.16 |
| 52 Week High | $19.37 | $57.65 |
| Indicator | IE | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 67.90 | 46.21 |
| Support Level | $17.10 | $48.84 |
| Resistance Level | $18.58 | $50.55 |
| Average True Range (ATR) | 1.07 | 1.64 |
| MACD | 0.09 | -0.30 |
| Stochastic Oscillator | 90.97 | 32.02 |
Ivanhoe Electric Inc is a United States-based d minerals exploration company with a focus on developing mines from mineral deposits principally located in the United States. The company has four business segments; Santa Cruz Project; critical metals; data processing services; and energy storage. It derives a majority of its revenue from Canada. The Santa Cruz Project and critical metals segments are focused on mineral project exploration and development. The data processing segment provides data analytics, geophysical modeling, and artificial intelligence services for the mineral, oil & gas, and water exploration industries. The energy storage segment develops, manufactures, and installs vanadium flow batteries for grid-scale energy storage.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.